Source-grounded facts extracted from BioScience Health Innovations, Inc.'s SEC 8-K filings across all families, newest first. Each cites a verbatim SEC excerpt.
BioScience Health Innovations, Inc.: Amended Restated Certificate of Incorporation to effect a 4-for-1 reverse stock split, effective September 10, 2025 (effective 2025-09-10).
“On September 10, 2025, BioScience Health Innovations, Inc. (the “Company”) amended its Restated Certificate of Incorporation (the “Certificate of Incorporation”), to effect a reverse split of the Company’s common stock on the basis that 4 (four) such shares of common stock shall become 1 (one) share of common stock.”
BioScience Health Innovations, Inc. completed an acquisition involving Best Labs, Inc. for 34,371,100 shares of the Company’s common stock, representing approximately 85.39% of the issued and outstanding shares (closed 2023-03-10).
“2023 (the “ Closing ”). As a result of the Exchange Agreement Best became the wholly-owned subsidiary of the Company. Upon the Closing, the Company issued the Best shareholders 34,371,100 shares of the Company’s common stock, representing approximately 85.39% of the issued and outstanding shares of the Company’s common stock following Closing, in exchange for all”
Justin Earl resigned as Chief Executive Officer at BioScience Health Innovations, Inc..
“Justin Earl tendered his resignation as the sole officer of the Company.”
John Chymboryk was appointed as Director at BioScience Health Innovations, Inc..
“Darren Lopez and John Chymboryk were appointed to serve on the Board of Directors with Justin Earl.”
Darren Lopez was appointed as Director at BioScience Health Innovations, Inc..
“Darren Lopez and John Chymboryk were appointed to serve on the Board of Directors with Justin Earl.”
Darren Lopez was appointed as Chief Executive Officer at BioScience Health Innovations, Inc..
“Darren López was appointed as the Chief Executive Officer of the Company.”
John Chymboryk was appointed as Chief Financial Officer at BioScience Health Innovations, Inc..
“On March 21, 2023, Nowtransit Inc. (the “Company”) appointed Mr. John Chymboryk as Chief Financial Officer of the Company, effective immediately.”
BioScience Health Innovations, Inc.: Company ceased being a shell company upon closing of the Exchange Agreement (effective 2023-03-10).
“As a result of the Closing of the Exchange Agreement, the Company ceased being a shell company, as that term is defined by Rule 12b-2 under the Securities Exchange Act of 1934.”
BioScience Health Innovations, Inc.: Changed fiscal year end from August 31 to December 31 (effective 2023-03-10).
“Simultaneously with the Closing, the Company changed its fiscal year end from August 31 to December 31 as a result of the Exchange to conform its fiscal year end to that of Best.”
BioScience Health Innovations, Inc. completed an acquisition involving Best Labs, Inc. and its shareholders (closed 2023-03-10).
“The transaction consummated on March 10, 2023 (the “Closing”). Upon the Closing, the Company issued the Best shareholders signatory 34,371,100 shares of the Company’s common stock, representing approximately 85.39% of the shares of the Company’s common stock to be outstanding, in exchange for all of the shares of Best common stock held by such Best shareholders (the “Exchange”).”
John Chymboryk was appointed as Director at BioScience Health Innovations, Inc..
“Darren Lopez and John Chymboryk were appointed to serve on the Board of Directors”
Darren Lopez was appointed as Director at BioScience Health Innovations, Inc..
“Darren Lopez and John Chymboryk were appointed to serve on the Board of Directors”
Darren Lopez was appointed as Chief Executive Officer at BioScience Health Innovations, Inc..
“Darren López was appointed as the Chief Executive Officer of the Company”
Justin Earl resigned as Officer at BioScience Health Innovations, Inc..
“Effective upon the Closing, Justin Earl tendered his resignation as the sole officer of the Company”
BioScience Health Innovations, Inc. entered into Share Exchange Agreement with Best Labs, Inc. and its shareholders (effective 2023-02-13).
“On February 13, 2023, Nowtransit Inc, a Nevada corporation. (the “Company”) entered into a Share Exchange Agreement (the “Exchange Agreement”) with Best Labs, Inc., a Nevada corporation (“Best”) and the shareholders of Best signatory thereto”
BioScience Health Innovations, Inc. entered into Stock Purchase Agreement with an accredited investor valued at $40,000 (effective 2022-11-22).
“On November 22, 2022, Nowtransit Inc. (the “Company”) entered into a Stock Purchase Agreement (the “Agreement”) with an accredited investor pursuant to which the Company sold to the purchaser 40,000 shares of the Company’s Series A Convertible Preferred Stock (the “Series A”) at a purchase price of $1.00 per share (the “Offering”).”
Justin Earl was appointed as President at BioScience Health Innovations, Inc..
“On July 29, 2021, Mr. Homici resigned as the Company’s director, President, Treasurer and Secretary and was replaced in each such role by Mr. Earl.”
Ivan Homici resigned as President at BioScience Health Innovations, Inc..
“On July 29, 2021, Mr. Homici resigned as the Company’s director, President, Treasurer and Secretary and was replaced in each such role by Mr. Earl.”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.